EMA Authorised: Yuvanci (macitentan;tadalafil) — Janssen-Cilag International NV

View source ↗

Summary

The EMA authorised Yuvanci, a fixed-dose combination of macitentan and tadalafil, for pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Yuvanci (macitentan; tadalafil)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Arterial Hypertension. MAH: Janssen-Cilag International NV. Decision date: 04/09/2025